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Abstract 
With the evolution in cardiovascular disease understanding 
and the application of advanced interventional therapies, 
antithrombotic medication has become the cornerstone of the 
medical management of cardiovascular patients. However, as 
older and new trials have confirmed, these drugs carry a 
substantial risk for hemorrhagic complications, especially from 
the gastrointestinal (GI) tract, which are accompanied by a 
significant mortality risk. In case of such an event, the clinician 
must decide whether to discontinue or not the medication and for 
how long, and he is called to balance the potential risk of 
thrombosis and recurrent bleeding. In this brief review, we 
present the studies which address this issue in order to elicit 
practical conclusions. (Rhythmos 2017;12(3): 45-49).  
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Introduction  
The benefits of antithrombotic therapy in atrial 
fibrillation, mechanical heart valves and secondary 
prevention of cardiovascular disease both in the clinical 
setting of acute coronary syndromes and stable ischemic 
heart disease are well established and the relevant drugs 
are officially recommended. 1-5 Even more so are the 
potential risks of intense antithrombotic therapy in terms 
of gastrointestinal (GI) bleeding (GIB). In the recent large 
trials of the novel anticoagulants, in patients with atrial 
fibrillation, the incidence of GIB in the warfarin arms 
ranged between 0.8-1.2%/year, while it was increased in 
the treatment arms, exceeding 2%. 6-9 Anti-platelet 
medications are associated with a GIB incidence of 1-2.5% 
roughly, as concluded by the studies which evaluated the 
conventional and novel agents, while antiplatelet 
combinations incur additional risk. 10-14 Moreover, GIB 
can carry a mortality risk of 2-4% up to over 25% for lower 
and upper GI tract respectively, depending on the severity 
of the hemorrhage and the patient comorbidities. 15,16 The 
bleeding risk when using antithrombotics is a known and 
acceptable hazard, as the benefits of therapy regarding the 
prevention of thrombotic events outweighs the potential 
harm from the hemorrhagic complications. However, the 
management of bleeding in the face of established 
indication of antithrombotic drug use is particularly 
problematic, especially because despite the frequency of 
this complication, there are very limited data in the 
literature to help us out.  
Antiplatelets and GI bleeding  
The consequences of stopping or temporarily 
interrupting antiplatelet therapy after a GIB event has been 
addressed in a few studies, almost exclusively with regard 
to aspirin. No data are available concerning the 
management of newer agents such as prasugrel or 
ticagrelor. Derogar et al studied retrospectively 118 
patients on low dose aspirin, treated for gastric ulcer 
bleeding. Those who discontinued their therapy had a 6-
fold increased risk of death or cardiovascular event in the 
first 6 months, a finding most prominent among patients 
with cardiovascular comorbidities. Patients who resumed 
aspirin therapy did so after a median interval of one week 
(33%) or immediately at discharge (67%). Rebleeding 
rates were too low in both groups and no statistical analysis 
is provided. 17  
In a similar but prospective trial, 156 patients with 
peptic ulcer bleeding taking low dose aspirin were 
randomly assigned to receive aspirin 80 mg/day or placebo 
immediately after successful endoscopic hemostasis for a 
period of 8 weeks. All participants were administered IV 
infusion of proton pump inhibitors followed by oral use. 
Recurrent hemorrhage occurred in 10.3% and 5.4% in 
treatment and control groups respectively, a difference 
statistically insignificant (hazard ratio 1.9, [CI, 0.6 to 6.0]), 
while the aspirin arm showed reduced all-cause mortality 
both at 30 days (hazard ratio, 0.2 [CI, 0.05 to 0.90]) and at 
8 weeks (hazard ratio, 0.2 [CI, 0.06 to 0.60]). Of note, 
deaths due to GIB were recorded within the first 5 days 
after the index event, while mortality in the placebo group 
was distributed throughout the entire 8-week time span. 18   
In the Danish study, more than 4500 patients with atrial 
fibrillation on antithrombotics were included after a GI 
bleeding event and 3409 were followed up from day 90 for 
a median of two years. The antithrombotic drugs were 
restarted in 73% and 55% of them received one or two 
antiplatelet agents. All-cause mortality was lower in the 
group of participants who restarted one antiplatelet agent 
(hazard ratio 0.76, CI 0.68 to 0.86) compared with those 
not resuming therapy. Thromboembolism was also 
reduced in association with restart of one antiplatelet agent 
(hazard ratio 0.76, CI 0.61 to 0.95). Antiplatelet 
medication did not increase hemorrhagic complications. 19  
Kim et al also examined retrospectively 72 patients 
who suffered a GIB event, while on antiplatelet (80%) or 
anticoagulant agents. Forty patients stopped the 
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antithrombotic drugs and 32 resumed or never interrupted 
therapy. Mean follow up duration was 26 months. 
Thrombotic events were significantly more in the 
discontinuation group patients who had a history of 
ischemic heart disease or cerebral infarct (P=0.001) but not 
in those without (P=0.635). Recurrent bleeding was 
equally observed in both groups. Mortality differences 
were also insignificant (p=0.581) but the absolute number 
of deaths was too low. 20  
In a different setting, low dose aspirin withdrawal 
preoperatively in order to avoid hemorrhagic 
complications, has been associated with cardiovascular 
events and the time of occurrence is of particular interest 
since acute cerebral events happen at 14.3 ± 11.3 days, 
acute coronary syndromes at 8.5 ± 3.6 days and acute 
peripheral arterial syndromes at 25.8 ± 18.1 days after 
aspirin discontinuation. In the same metaanalysis 
uninterrupted aspirin therapy increased the frequency of 
bleeding complications 1.5 times, but it did not affect their 
severity in non- intracranial surgery. 21   
Anticoagulants and GI bleeding  
Anticoagulant management in case of GIB has been 
somewhat more investigated. In the Danish study, 22% of 
the patients who resumed therapy received one 
anticoagulant and 11% received a combination of 
anticoagulant and one antiplatelet drug. All-cause 
mortality and thromboembolic events were significantly 
lower in both cohorts that continued therapy [HR 0.39 
(0.34-0.46) and 0.41 (HR 0.32-0.52) respectively]. Major 
bleeding was higher in those receiving a single 
anticoagulant [HR 1.37 (1.06-1.77)], while it hardly 
missed statistical significance in the double therapy group 
[HR 1.44 (1.00-2.08)]. Recurrent GI bleeding did not differ 
between patients who resumed any therapy and those who 
did not. 19  
Lee et al studied retrospectively 58 patients on 
warfarin, admitted due to non-variceal upper GI bleeding, 
and compared them with controls taking aspirin as 
secondary prevention from ischemic heart disease. Mean 
follow up duration was 9 months. All participants received 
the standard medical and interventional or surgical 
therapy. Thirty-six subjects from the warfarin group (62%) 
ceased therapy and 6 of them suffered a thromboembolic 
event between the 21st and 75th day of follow up, 
significantly more compared with the aspirin group. 
Recurrent bleeding was also more frequent in patients on 
warfarin with the hemorrhages occurring within the first 
14 days. 22  
In another retrospective study, 442 patients with GIB 
while on warfarin were followed up for 3 months. Therapy 
was resumed in 260 of them (58.8%) with a median 
interruption interval of 4 days and it resulted in lower risk 
for thrombosis (HR 0.05; 95% CI, 0.01-0.58) and death 
(HR, 0.31; 95% CI, 0.15-0.62), without significantly 
increasing the risk for recurrent GIB (HR, 1.32; 95% CI, 
0.50-3.57), except for those restarting therapy within the 
first 7 days. Patients who did not interrupt warfarin for 
more than 14 days, exhibited no thrombosis. 23 Similar 
results were reported by Qureshi et al who examined the 
records of 1329 patients with atrial fibrillation on warfarin 
presenting with major GIB. Almost half of them restarted 
anticoagulant therapy (49%). Warfarin resumption was 
associated with lower risk of thromboembolism (HR 0.71, 
CI 0.54 to 0.93, p= 0.01) and mortality (HR 0.67, CI 0.56 
to 0.81, p <0.0001) without affecting recurrent GIB (HR 
1.18, CI 0.94 to 1.10, p=0.47). When the analysis included 
the time of restarting therapy in days post the index event, 
it was shown that resuming warfarin 7 days compared with 
30 days after the hemorrhagic episode was related with a 
reduced mortality (HR 0.56, 0.33-0.98, p=0.04) and a trend 
towards reduced thromboembolism, with no difference in 
recurrent bleeding. 24  
In a different analysis according to CHADS2 and 
HASBLED scores, the outcomes of relatively early (15-30 
days) restart of anticoagulation were compared with a 
delayed one (after 30 days). The risk of stroke within 12 
months was clearly smaller with earlier re-initiation group 
in all patients. Recurrent bleeding within three months was 
twice as high only in patients with a high HAS-BLED 
score (>3). 25  
Sengupta et al followed prospectively 197 patients with 
GIB while on anticoagulants. The drugs were discontinued 
at discharge in 39% of the subjects. Continuation of 
therapy was associated with decreased major thrombotic 
episodes within 90 days (HR 0.121, CI 0.006–0.812, P 
=0.03), while no significant difference was noted with 
regard to recurrent GIB (HR 2.17, CI 0.861–6.67, P =0.10) 
or death within the same follow up period (HR 0.632, CI 
0.216–1.89, P =0.40). In this study, most participants were 
taking warfarin (74%), enoxaparin (8%) or unfractionated 
heparin (6%). Patients on novel oral anticoagulants were 
included but they represented a small percentage (13% in 
total). 26   
Table 1. CHADS2 score and annual incidence of stroke 
 
CHADS2 score Stroke rate (%/year) 
0 1.9 
1 2.8 
2 4 
3 5.9 
4 8.5 
5 12.5 
6 18.2 
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Table 2. CHA2DS2VASc score and annual incidence of 
stroke 
CHA2DS2VASc 
score 
Stroke rate (%/year) 
0 0 
1 1.3 
2 2.2 
3 3.2 
4 4 
5 6.7 
6 9.8 
7 9.6 
8 6.7 
9 15.2  
Reaching a decision  
It is rarely feasible to come to a safe conclusion on the 
absolute need and timing of antithrombotic therapy re-
establishment after a bleeding episode. Each case should 
be individualized and potential risks should be taken into 
account. At first, the thrombotic and bleeding risk should 
be assessed. In patients on antiplatelet medication, clinical 
conditions constituting a high thrombotic risk include a 
recent acute coronary event (up to 12 months old), and 
recent coronary angioplasty and stenting (at least 1 month 
for bare metal and 6-12 months for drug-eluting stents). 
The risk is small when the drugs are used for primary 
prevention. 27 When dealing with atrial fibrillation and 
anticoagulation is needed, the risk can be stratified 
according to the CHADS2 and CHA2DS2VASc scores as 
shown on Tables 1 and 2. 28,29 The thromboembolic risk in 
the presence of mechanical valves depends on both the 
technical aspects of the prosthesis and the comorbidities of 
the patient. A rough estimation is provided in Table 3. 
5,27,30,31  
The bleeding risk is also a function of the patient’s 
comorbidities and the clinical and laboratory status during 
the index GI hemorrhagic event. As far as the former 
parameters are concerned, several scoring systems have 
been developed to predict the chance of bleeding 
complications from vitamin K antagonists, but two of them 
are the most commonly used, the HAS-BLED and the 
ATRIA scores (Table 4). 32-34  With regard to the latter 
parameters, the most well-known score for predicting the 
possibility of recurrent hemorrhage is the Rockall score 
(Table 5). 35  
The balance between thrombotic and hemorrhagic risk 
will be the criterion for setting priorities. If bleeding risk is 
excessive and thrombotic events less likely, 
antithrombotics will be withheld for a longer period of 
time. If the thrombotic risk is high instead, the interruption 
has to be as short as possible. In the studies presented 
earlier, patients on antithrombotic medication admitted for 
GI hemorrhage, stopped or temporarily interrupted their 
drugs and were followed up for a period ranging from 8 
weeks to 24 months. Drug interruption lasted between 4 
and 30 days roughly. In most of the studies, 
discontinuation of therapy resulted in an excess of 
thrombotic episodes and increased mortality, without a 
significant reduction in bleeding recurrencies. It should be 
noted, that these results apply the most to patients who 
need antithrombotics for secondary cardiovascular 
prevention, or have atrial fibrillation with a clear indication 
for anticoagulation.   
 
Table 3. Thrombotic risk stratification (for patients with 
indication for anticoagulants) 
AF = atrial fibrillation; AoV = aortic valve; CHF = congestive 
heart failure; DM = diabetes mellitus; HTN = hypertension; MV 
= mitral valve; TIA = transient ischemic attack  
Table 4. Scoring systems predicting bleeding risk in 
patients with AF receiving VKAs 
HAS-BLED score ATRIA score 
Clinical parameter points Clinical 
parameter 
points 
Hypertension 1 Anemia 3 
Abnormal renal and 
liver function (1 
point each) 
1 or 2 Severe renal 
disease (GFR < 
30 ml/min) 
3 
Stroke 1 Age >75 years 2 
Bleeding 1 Prior hemorrhage 
diagnosis 
1 
Labile INRs 1 Hypertension 1 
Elderly (e.g. age 
>65 years) 
1  
Drugs or alcohol (1 
point each) Drugs or 
alcohol (1 point 
each) 
1 or 2 
0-1: low risk (<1.5%/year) 
2:  moderate risk (≈2%/year) 
≥3: high risk (>4%/year) 
0-3: low risk (<1%/year) 
4: moderate risk (1-5%/year) 
5-10: high risk (5-17%/year) 
Risk High 
(>10% / year) 
Moderate 
(4-10% / year) 
Low 
(≤4% / year) 
Mechanical 
heart valve 
 
 
 
 
 
 
AF 
MV prosthesis 
Caged-ball or 
tilting disc 
AoV prosthesis 
Recent (within 
6 months) 
stroke or TIA 
 
CHADS2 
score 5-6 
CHA2DS2VA
Sc score 8-9 
Bileaflet AoV 
prosthesis & >1 
of following 
risk factors: AF, 
prior stroke or 
TIA, HTN, DM, 
CHF, age >75 y 
 
CHADS2 score 
3-4 
CHA2DS2VASc 
score 5-7 
Bileaflet 
aortic valve 
prosthesis 
without AF 
and no other 
risk factors 
for stroke  
 
 
CHADS2 0-2 
CHA2DS2VAS
0-4  
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It is also interesting that in most studies, thrombotic 
complications occurred constantly beyond the 10th day of 
drug interruption, while recurrent bleeding episodes were 
noted within the first 7-14 days. Moreover, when the 
results were analyzed according to the interruption 
interval, restarting warfarin at 7-21 days carried a mortality 
benefit, while earlier administration of the anticoagulant 
was associated with excess rate of rebleeding.24 
Furthermore, following discontinuation of aspirin, 
coronary syndromes, cerebrovascular and peripheral 
arterial events occured around the 8th, 14th and 26th day 
respectively.  
 
Table 5. Estimation of recurrent GI bleeding rates (Rockall 
score) 
 
Parameter Score 
 0 1 2 3 
Age <60 60-79 >80  
Hemodynamic 
instability 
No SBP >100 
mmHg 
HR>100 
bpm 
SBO <100 
mmHg 
 
Comorbidity No  Heart 
failure, 
Ischemic 
heart 
disease 
Renal 
failure 
Liver 
failure 
Metastatic 
cancer 
Diagnosis Mallory
-Weiss 
All other 
diagnoses 
GI 
malignancy 
 
Evidence of 
bleeding 
None  Blood, 
adherent 
clot, 
spurting 
vessel 
 
Score ≤5: risk for recurrent bleeding ≤14.1% and risk of death 
≤5.3%; score >5: risk of recurrent bleeding ≥24.1% and risk of death 
≥10.8% 35,36 
 
Thus, in conclusion, after taking into account the 
thrombotic and bleeding risk of the individual patient and 
assess the power of the indication for certain 
antithrombotic medications, it appears prudent to withhold 
the drugs for the first 7-14 days to avoid recurrent 
hemorrhage and to re-institute therapy thereafter to benefit 
from the reduction in thromboembolism and possibly 
mortality. Needless to say, all patients should be offered 
appropriate medical treatment for the GI bleeding with 
proton pump inhibitors, H. pylori eradication, reversal of 
antithrombotic effect, endoscopic hemostasis and 
interventional or surgical therapy according to current 
guidelines. However, important knowledge gaps still exist 
in the literature. Restarting double antiplatelet or triple 
antithrombotic medication has not been tested, although it 
is used in a significant number of patients with coronary 
artery disease. Novel antiplatelets and anticoagulants have 
not been used in the relevant trials or they are represented 
in so small numbers that preclude any conclusions from 
being drawn. Moreover, the existing data are derived not 
exclusively, but mostly, from retrospective studies, which 
limit the value of these data. Hence, more research is 
needed on the subject, as imperative questions on everyday 
clinical problems still seek an answer.     
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